Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Lymphoma
Interventions: sargramostim, methotrexate, pegylated liposomal doxorubicin hydrochloride, vincristine sulfate; Biological · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Mechanical Ventilation Complication, Upper Airway Obstruction
Interventions: nasal mask, full face mask; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19, Critical Illness, ICU Acquired Weakness, PICS, Cardiorespiratory Fitness
Interventions: REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT); Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Birmingham, Alabama • Lexington, Kentucky • Durham, North Carolina + 2 more

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: Venetoclax, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: New York, New York • Nashville, Tennessee

Conditions: Chlamydia Infections, Gonorrhea, Trichomonas Infections
Interventions: APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays; Device
Lead sponsor: Gen-Probe, Incorporated; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 1,336 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 14
States / cities: Birmingham, Alabama • San Diego, California • North Miami, Florida + 11 more

Conditions: Asthma
Interventions: Targeted text messages, General text messages; Behavioral
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 4 Years to 17 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions: doxorubicin, bortezomib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Neoplasms
Interventions: Telcyta, Liposomal Doxorubicin; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 63
States / cities: Casa Grande, Arizona • Little Rock, Arkansas • Antioch, California + 49 more

Conditions: Hodgkin Disease
Interventions: Filgrastim SD/01, Adriamycin, Bleomycin, Vinblastine, DTIC; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma, B-Cell
Interventions: obinutuzumab, cyclophosphamide, doxorubicin, prednisone, vincristine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 38
States / cities: Birmingham, Alabama • Encinitas, California • Aurora, Colorado + 34 more

Conditions: Cardiac Toxicity, Lymphoma
Interventions: bleomycin sulfate, filgrastim, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 57
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 45 more

Conditions: Oral Mucositis, Periodontal Diseases, Cancer
Interventions: Telehealth Intervention (THI); Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Uterine Cancer, Mesotheliomas, Gastrointestinal Cancers, Cervical Cancer
Interventions: HIPEC: MMC 30mg @ T0, 10mg @ T45min, HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0, HIPEC: CDDP 75 mg/m2 @T0, HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0; Device
Lead sponsor: Bay Area Gynecology Oncology; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 1
States / cities: Los Gatos, California

Conditions: PreDiabetes
Interventions: Episodic Future Thinking, Episodic Recent Thinking, Scarcity Narrative, Neutral Narrative; Behavioral
Lead sponsor: Leonard Epstein; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Buffalo, New York • Roanoke, Virginia

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
Interventions: GTAEXS617, SoC; Drug
Lead sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more

Conditions: Thoracic Surgery
Interventions: Sham serratus anterior plane block, Serratus anterior plane block; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 6
States / cities: Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 3 more

Conditions: Infections, Heart Diseases, Lung Diseases, Kidney Diseases, Liver Diseases, Gastrointestinal Diseases
Interventions: Synapse medicine platform; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 1,485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Racism, Healthcare Disparities, Minority Health
Interventions: Non-verbal communication score; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Lymphoma
Interventions: Lenalidomide, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumor
Interventions: VX-984 120 mg + PLD 40 mg/m^2, VX-984 240 mg + PLD 40 mg/m^2, VX-984 480 mg + PLD 40 mg/m^2, VX-984 720 mg + PLD 40 mg/m^2; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee + 2 more

Conditions: Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: capecitabine, carboplatin, epirubicin hydrochloride; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 3
States / cities: Bethesda, Maryland • Portsmouth, Virginia

Conditions: Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
Interventions: Olvi-Vec, Platinum-doublet with or without bevacizumab; Biological · Drug
Lead sponsor: Genelux Corporation; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Newport Beach, California • Orlando, Florida

Conditions: Wellness, Self Compassion, Burnout, Anxiety, Depression
Interventions: App-based bundled mental fitness intervention, App-based wellness module collection; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Neuromuscular Blockade
Interventions: Sugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW, Sugammadex 4 mg/kg IBW, Neostigmine + Glycopyrrolate, Rocuronium or Vecuronium; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 13
States / cities: Sacramento, California • Miami, Florida • Kansas City, Kansas + 9 more

Search by objective public record fields.

Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma

Nasal Mask Ventilation During the Induction of General Anesthesia

REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays

Use of Text Messages to Improve Care For Children Following an ED Visit for Asthma

Doxorubicin and Bortezomib in Treating Patients With Liver Cancer

Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer

Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)

Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy

MINDD 3: Prediabetes and Delay Discounting

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Ultrasound-Guided Serratus Anterior Plane Block for Additional Pain Relief After Lung Surgery

Effect of Synapse Medicine Decision Support on Inpatient Pharmacist Efficacy and Efficiency

Assessing Patient-provider Interactions During the Preoperative Anesthesia Consult

A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

A Study of a Mental Fitness Intervention for Anesthesiology Resident Wellbeing and Self-Compassion

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)